ClinicalTrials.gov record
Completed Phase 1 Interventional

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

ClinicalTrials.gov ID: NCT02165345

Public ClinicalTrials.gov record NCT02165345. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 11:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis

Study identification

NCT ID
NCT02165345
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
82 participants

Conditions and interventions

Interventions

  • Tocilizumab Drug

Drug

Eligibility (public fields only)

Age range
2 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 15, 2014
Primary completion
Nov 23, 2021
Completion
Nov 23, 2021
Last update posted
Feb 22, 2022

2014 – 2021

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
9
Facility City State ZIP Site status
Arkansas Children's Hospital Research Institute Little Rock Arkansas 72202
University of Chicago Hospital Chicago Illinois 60637
Hackensack University Medical Center; Pediatric Rheumatology Hackensack New Jersey 07601
Duke University Durham North Carolina 27705
Cincinnati Children'S Hospital Medical Center; Division of Rheumatology Cincinnati Ohio 45229-3039
Cleveland Clinic Fndn Cleveland Ohio 44195
Healthcare Research Consultants Tulsa Oklahoma 74135
University of Utah; Immunology/Rheumatology/Allergy Salt Lake City Utah 84109
Seattle Children's Hospital Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02165345, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 22, 2022 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02165345 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →